Viewing Study NCT02846935

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:40 PM
Ignite Modification Date: 2026-02-11 @ 9:37 PM
Study NCT ID: NCT02846935
Status: COMPLETED
Last Update Posted: 2019-01-07
First Post: 2016-07-25
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
Sponsor: Yogen Saunthararajah
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None T-cell Lymphoma View
None Aggressive B-cell Lymphoma View
None Non-Hodgkin's Lymphomas View
None Indolent B-cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None p16/CDKN2A View
None TP53 View
None THU View
None Decitabine View
None Tetrahydrouridine View
None DEC View